Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HMR's Arava May Be Ripe For Review By Cigna Soon After 6-Month Delay

Executive Summary

Hoechst Marion Roussel's arthritis immunotherapy Arava is likely to be considered for coverage by the large Cigna Healthcare prescription plan, which represents about 1% of total U.S annual drug purchases.

You may also be interested in...

Avandia 90% Formulary Acceptance Achieved At One Month Post-Launch - SB

SmithKline Beecham/Bristol-Myers Squibb's Avandia has been "very quickly embraced" by managed care and is reimbursed by 90% of plans, SmithKline Beecham Chief Operating Officer Jean-Pierre Garnier, PhD, reported Sept. 16 at the Bear Stearns health care conference in New York City.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts